I-Mab (IMAB) Competitors

I-Mab (NASDAQ:IMAB) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk.

Does the MarketBeat Community favor IMAB or GLUE?

I-Mab received 45 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 64.13% of users gave I-Mab an outperform vote while only 46.67% of users gave Monte Rosa Therapeutics an outperform vote.

Company	Underperform	Outperform
I-Mab	Outperform Votes 59 64.13%	Underperform Votes 33 35.87%
Monte Rosa Therapeutics	Outperform Votes 14 46.67%	Underperform Votes 16 53.33%

Does the media favor IMAB or GLUE?

In the previous week, Monte Rosa Therapeutics had 2 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Monte Rosa Therapeutics and 1 mentions for I-Mab. Monte Rosa Therapeutics' average media sentiment score of 1.94 beat I-Mab's score of 0.47 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monte Rosa Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is IMAB or GLUE more profitable?

I-Mab's return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Monte Rosa Therapeutics	N/A	-62.68%	-38.83%

Which has stronger earnings and valuation, IMAB or GLUE?

Monte Rosa Therapeutics has lower revenue, but higher earnings than I-Mab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	22.42	-$206.44M	N/A	N/A
Monte Rosa Therapeutics	N/A	N/A	-$135.35M	-$1.83	-3.09

Do insiders & institutionals believe in IMAB or GLUE?

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 6.5% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Do analysts rate IMAB or GLUE?

I-Mab presently has a consensus target price of $8.00, suggesting a potential upside of 647.66%. Monte Rosa Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 147.35%. Given I-Mab's stronger consensus rating and higher possible upside, equities research analysts clearly believe I-Mab is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Monte Rosa Therapeutics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Which has more volatility and risk, IMAB or GLUE?

I-Mab has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Summary

I-Mab beats Monte Rosa Therapeutics on 9 of the 14 factors compared between the two stocks.